Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Intera Oncology
AddedFeb 16, 2024
UpdatedJun 18, 2026
Intera Oncology

Intera Oncology

Seed

Intera Oncology, a specialist in colorectal and cholangiocarcinoma treatments, acquires and improves oncology drugs.

HQ
Wellesley, MA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Intera Oncology, founded with a mission to enhance the survival rates of colorectal cancer and cholangiocarcinoma patients, specializes in acquiring and improving oncology drugs. The company focuses on innovative drug delivery systems, particularly the Hepatic Arterial Infusion (HAI) therapy, which directly targets liver tumors. Their flagship product, the Intera 3000 HAI Pump, exemplifies their commitment to providing advanced treatment options for patients battling these aggressive cancers.

Notable figures associated with Intera Oncology include key leaders from the medical and pharmaceutical industries, although specific names are not detailed. The company has achieved significant milestones by acquiring drug delivery products from Johnson & Johnson, demonstrating their capability to handle and enhance complex oncology treatments. Intera Oncology's impact is evident in its contribution to extending patient survival and improving the quality of life for those affected by colorectal cancer and cholangiocarcinoma.

Intera Oncology - Similar Companies

OncoSpherix logo

OncoSpherix

oncospherix.com

Intio logo

Intio

InterCure logo

InterCure

intercure.com

ImageneBio logo

ImageneBio

ikenaoncology.com

Champions Oncology logo

Champions Oncology

Core Oncology logo

Core Oncology

Cullinan Oncology logo

Cullinan Oncology

Oncology Honduras logo

Oncology Honduras

Advanced Chemotherapy Technologies logo

Advanced Chemotherapy Technologies

Onc.AI logo

Onc.AI

onc.ai

Oncospace logo

Oncospace

oncospace.com

OncoPrecision logo

OncoPrecision

oncoprecision.bio

Oncolix logo

Oncolix

Oncternal Therapeutics logo

Oncternal Therapeutics

oncternal.com

Istari Oncology logo

Istari Oncology

istarioncology.com

Intera Oncology - Quick Facts

Who are Intera Oncology's competitors?

Companies similar to Intera Oncology include OncoSpherix, Intio, InterCure and ImageneBio.

When was Intera Oncology founded?

Intera Oncology was founded in 2019.

Where is Intera Oncology's headquarters located?

Intera Oncology's headquarters is located in Wellesley, MA, US.

When was Intera Oncology's last funding round?

Intera Oncology's most recent funding round was for $413.5k (USD) in August 2021.

How much has Intera Oncology raised to-date?

As of Aug 10, 2021, Intera Oncology has raised a total of $3.7M (USD).

How many employees does Intera Oncology have?

Intera Oncology has 37 employees as of Feb 5, 2024.

Intera Oncology - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Drug Delivery
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Oncology Drugs
Tags
  • Biotech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified